Key result
Device-based therapies offer promising adjunctive treatment for resistant hypertension despite ongoing clinical and economic challenges.
Why the study?
Despite widely available antihypertensive medications, blood pressure remains uncontrolled in a sizable population, highlighting the unmet need for novel device-based therapies.
This review highlights the evolving landscape of device-based therapies for resistant hypertension, emphasizing their potential as adjuncts to medical therapy while outlining the barriers to their clinical integration.
Supports cautious adjunctive consideration of approved devices in resistant hypertension; leaves open broader adoption pending definitive RCTs.
Hypertension is the most prevalent modifiable risk factor associated with cardiovascular mortality. The World Health Organization (WHO) estimates that hypertension directly or indirectly causes the death of at least nine million people globally every year. The number of people living with hypertension (blood pressure (BP) of ≥140 mmHg systolic or ≥90 mmHg diastolic or on medication) doubled between 1990 and 2019, from 650 million to 1.3 billion. Despite a plethora of antihypertensive drugs widely available, a sizable part of the antihypertensive population stays uncontrolled. The unmet need of controlling BP in this population may be addressed, in part, by developing new drugs and devices/procedures to treat hypertension and its comorbidities. Several device-based approaches have been introduced to lower BP, and most of these strategies aim to modulate autonomic nervous system activity. Importantly, when considering a device-based treatment, each patient's underlying pathophysiology is considered, and the procedural risks are weighed against the cardiovascular risk attributed to the elevated BP. In November 2023, the FDA approved two renal denervation (RDN) devices. This manuscript discusses current interventional devices and procedures recently approved (RDN) and others in the clinical testing stage for arterial hypertension intervention or management. As we list below, all others have shown promising results and are being evaluated on a larger clinical trial. The new device-based classes are as follows: catheter-based RDN, baroreflex amplification, arteriovenous (AV) malformation, carotid body (CB) ablation, pacemaker-based cardiac neuromodulation, electro-acupuncture, and deep brain stimulation. Baroreflex amplification uses peripheral neuromodulation, while AV malformation leverages AV anastomosis. CB ablation modulates chemoreceptors, and pacemaker-based neuromodulation adjusts atrioventricular intervals. Electro-acupuncture proves potential, and deep brain stimulation offers central nervous system intervention.
No takes yet. Share an insight, caveat, or question.
Tolu-Akinnawo et al. (2024) conducted a review in Resistant Hypertension. Device-based therapies (e.g., renal denervation, baroreflex amplification) was evaluated. Device-based therapies, including renal denervation and baroreflex amplification, offer promising adjunctive treatments for resistant hypertension despite ongoing clinical, technical, and economic challenges.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: